Analyst picks & changes
Interneuron Pharmaceuticals Inc.
(IPIC)
Jeffrey Kraws of Montgomery Securities maintained a "buy" following publication of a paper in the Journal of Pharmacology and Experimental Therapeutics critical of d-fenfluramine. IPIC
Gathering data...
Interneuron Pharmaceuticals Inc.
(IPIC)
Jeffrey Kraws of Montgomery Securities maintained a "buy" following publication of a paper in the Journal of Pharmacology and Experimental Therapeutics critical of d-fenfluramine. IPIC